ROP in the Era of Anti-VEGF

R.V. Paul Chan, MD, MSc, MBA, FACS, Timothy G. Murray, MD, MBA

Show Description +

R.V. Paul Chan, MD, MSc, MBA, FACS, discusses the studies that are showing anti-VEGF's efficacy as a first-line therapy for ROP and how it is changing the treatment paradigm.

Posted: 2/23/2021

Keywords:

Anti-VEGF

•

Retinopathy of prematurity, ROP,

•

retina-meeting-recap

Up Next

Name: ROP in the Era of Anti-VEGF
Uploaded: 2021-02-23T19:06:12+00:00
Description: R.V. Paul Chan, MD, MSc, MBA, FACS, discusses the studies that are showing anti-VEGF's efficacy as a first-line therapy for ROP and how it is changing the treatment paradigm.

Advancements in Retinal Detachment Repair

Maria H. Berrocal, MD, Timothy G. Murray, MD, MBA

The Promise of Macular Reconstruction

Timothy W. Olsen, MD, Timothy G. Murray, MD, MBA

An Update on Brolucizumab One Year Later

Ryan Rich, MD; Timothy G. Murray, MD

The Benefits of Anti-VEGF for Advanced Vision Loss in Wet AMD

Dennis Han, MD; Timothy G. Murray, MD

Diabetic Retinopathy: Treat Them Early

Maria H. Berrocal, MD; Timothy G. Murray, MD

Track the History–and Future–of Anti-VEGF

Robert Avery, MD; Timothy G. Murray, MD

ARDS Stays In-Person, Safely

Timothy G. Murray, MD, MBA

An Update on Surgical Approaches to Gene and Cell Therapies

Allen C. Ho, MD, Timothy G. Murray, MD, MBA

Back to All Videos